Abstract
Through cDNA array analyses and immunohistochemistry on tissue microarrays, trefoil factor 3 (TFF3) was recently shown to be overexpressed in prostate cancer. The purpose of this study was to test the feasibility of using the levels of trefoil factors as a plasma marker for prostate cancer. In 79 patients with prostate cancer, 23 patients with benign prostatic hyperplasia, and 44 healthy individuals plasma TFF1, TFF2, and TFF3 were determined with ELISAs and compared with clinical stage and prostate-specific antigen (PSA) values. Plasma levels of TFF were compared with the immunohistochemical expression of TFF and chromogranin A in 30 prostate cancer tissue samples. Patients with advanced prostate cancer had significantly higher plasma concentrations of TFF1, TFF2, and TFF3 (P < 0.01) compared with patients with localized disease. Using a cutoff of 200 pmol/L, the sensitivity and specificity of plasma TFF3 in differentiating between patients with localized and advanced disease was 74% (59-85%) and 81% (66-91%). Plasma levels of TFF3 were highest in patients with bone metastases (P = 0.008). Patients with serum PSA >10 microg/L had significantly higher plasma TFF3 values than patients with serum PSA <10 microg/L (P = 0.03) and TFF3 levels were higher in patients with Gleason sums of > or = 7 (P = 0.02). Expression of TFF1 and TFF3 determined by immunohistochemistry was increased in patients with prostate cancer but did not correlate with plasma trefoil factor values. Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Prospective studies are needed to confirm the predictive utility of trefoil factors in prostate cancer.
Highlights
Purpose:Through cDNA array analyses and immunohistochemistry on tissue microarrays, trefoil factor 3 (TFF3) was recently shown to be overexpressed in prostate cancer
TFF1-3 was measured in plasma samples from 23 patients with histologically confirmed benign prostatic hyperplasia www.aacrjournals.org
The discovery that trefoil peptides (TFF1 and TFF3) are overexpressed in prostate cancer tissue has suggested that these peptides may be valuable for the screening of biological fluids
Summary
Purpose:Through cDNA array analyses and immunohistochemistry on tissue microarrays, trefoil factor 3 (TFF3) was recently shown to be overexpressed in prostate cancer. The purpose of this study was to test the feasibility of using the levels of trefoil factors as a plasma marker for prostate cancer. Expression ofTFF1andTFF3 determined by immunohistochemistry was increased in patients with prostate cancer but did not correlate with plasma trefoil factor values. Conclusions: Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Through cDNA array analyses and immunohistochemistry on prostate cancer tissue arrays, trefoil factor 3 (TFF3) was recently shown to be overexpressed in prostate cancer (2 – 6). Requests for reprints : Else Marie Vestergaard, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby Hospital, Brendstrupgaardsvej, DK-8200 Aarhus N, Denmark. Members of the trefoil peptide family have been observed to be overexpressed in a variety of cancers, including intestinal, pancreas, and prostate cancers (6, 8, 17 – 19) and function as scatter factors, proinvasive, antiapoptotic, and angiogenic agents (17, 20 – 23)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
